were approximately 24. This is very similar to previous studies of omadacycline against S. pneumoniae (stasis AUC/MIC 18) and other PK/PD evaluations of tetracycline-class antibiotics. 1-log kill targets were only 2-3 fold more than stasis targets for each strain. This data should provide useful in the dose-regimen optimization of omadacycline.
E. coli
MIC (ug/mL) Conclusion. DLX 300 mg IV, q12hr, should achieve fAUC24/MIC ratios that are adequate to treat ABSSSI caused by most contemporary isolates of EC and PA. For EC, isolates with DLX MICs ≤0.25 μg/mL comprised 73% of all isolates. For PA, isolates with DLX MICs ≤1 μg/mL comprised 88% of all isolates. Similar results would be expected for TAP with oral DLX 450 mg, q12hr.
Disclosures. R. Hoover, Melinta Therapeutics: Consultant, Consulting fee; A. Marra, Melinta Therapeutics: Employee, Salary; E. Duffy, Melinta Therapeutics: Employee, Salary; S. K. Cammarata, Melinta Therapeutics: Employee, Salary Friday, October 6, 2017: 12:30 PM Background. Intra-abdominal candidiasis (IAC) is a prominent invasive fungal infection associated with high mortality. Prompt antifungal therapy and source control are crucial for successful treatment. Echinocandin antifungal drugs are first-line agents. Yet, their clinical effectiveness is highly variable with known potential for breakthrough resistance, and little is known about drug exposure at the site of infection. Using matrix-assisted desorption/ionization (MALDI) mass spectrometry imaging as well as standard analytical techniques, we investigated the spatial and quantitative distribution in tissue lesions for two echinocandin drugs, micafungin and CD101, in a clinically relevant IAC mouse model.
Unraveling Drug Penetration of Echinocandin
Methods. Female 6-8 week old CD1 mice weighing 18-22 g were infected intraperitoneally (IP) with 1 × 10 7 CFU of C. albicans SC5314 mixed with sterile stool matrix. Single IP doses of CD101 at 5 or 20 mg/kg (equivalent to humanized therapeutic dose) or micafungin at 5 mg/kg (therapeutic dose) were administered to mice at day 3 post-inoculation. Mice were sacrificed at just before antifungal treatment (n= 1), and at 1, 3, 6, 24, and 48 hours post-dose (n = 3 per group per time point). Liver and kidney lesions were collected for MALDI imaging. Laser capture microdissection (LCM) followed by liquid chromatography coupled tandem mass spectrometry (LC/ MS-MS) was applied to 6 and 24 hours samples for drug exposure measurement. In a separate experiment, mice were treated with 2 or 3 doses of micafungin (5 mg/kg), or a single dose of CD101 (20 mg/kg). Drug accumulation was analyzed at 48 and 72hours post the first dose.
Results. Drug accumulation within lesions was observed with both drugs at their humanized therapeutic dose. However, micafungin, even at steady-state, failed to approach the mutant prevention concentration (MPC) (16 µg/mL) of the infecting strain. CD101 demonstrated extensive penetration into the lesions after a single dose administration and persisted in lesions at above MPC level of 29.7 µg/mL at 72 hours postdose.
Conclusion. These findings indicate that current echinocandin drugs may be limited by penetration at the site of infection, which have implications for clinical outcomes and emergence of resistance in patients with IAC. Background. Acinetobacter baumannii has become a major cause of nosocomial infections worldwide due to highly resistance to various groups of antibacterial agents. This in vitro study was determine the MICs for sulbactam, colistin, fosfomycin sodium individually and synergistic activity of both in combination with biapenem against multidrug-resistant A. baumannii.
Methods. The MICs and synergistic interaction of sulbactam, colistin, fosfomycin sodium and biapenem were determined according to the Clinical and Laboratory Standards Institute (CLSI) guidelines (2016) by the chequerboard technique. 40 clinical MDR-Acinetobacter baumannii isolates from 13 tertiarycare hospitals in Thailand were tested. The synergistic effect was evaluated by the fractional inhibitory concentration index (FICI).
Results. The MICs for MDR-Acinetobacter baumannii results of biapenem and other agents are shown in Figure 1 . The FICI results showed all 40 strains (100%) had an FICI ≤ 0.5, suggesting a synergistic effect of colistin in combination with biapenem (Table 1) . MICs of mostly strains were decreased two to four doubling dilutions for both antibacterial agents. Moreover, 95% of isolates have MICs to colistin and fosfomycin sodium lower than sensitivity breakpoint when combined with biapenem. The result showed no data on the antagonistic effect (FICI ˃4) of all biapenem-based combination.
Conclusion. The combination of colistin or fosfomycin sodium with biapenem show synergistic pattern and MICs improvement for all strains. For that reason, the use of colistin, fosfomycin sodium combined with biapenem could be a promising treatment option for MDR-Acinetobacter baumannii. FIGURE 1. MIC for multidrug resistant Acinetobacter baumannii biapenem (n = 63), sulbactam (n = 40), colistin (n = 40), and fosfomycin sodium(n = 40).
